PAPablo Aja-Macaya

Pablo Aja-Macaya

*This is an algorithmically generated author record based on publicly available information.

Pablo Aja-Macaya has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Germán Bou

    Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña

    7 shared publications
  • Jorge Arca-Suárez

    Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña

    6 shared publications
  • Tania Blanco-Martín

    Grupo de Investigación en Microbiología. Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), Sergas, Universidade da Coruña

    6 shared publications
  • Gloria Pérez-Rodríguez

    Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC)

    5 shared publications
  • Lucía González-Pinto

    Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña

    5 shared publications
  • Lucía Sánchez-Peña

    Servicio de Microbiología Clínica, Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña

    5 shared publications

Latest Publications

  • Open Access

    In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2

    by Gloria Pérez-Rodríguez, Lucía González-Pinto, Pablo Aja-Macaya, Carlos Molina-Cáceres, Lucía Sánchez-Peña, Tania Blanco-Martín, Antonio Oliver, Germán Bou, Jorge Arca-Suárez

    The emergence of ceftazidime/avibactam resistance in an extended-spectrum β-lactamase (ESBL)-producing Pseudomonas aeruginosa isolate during ceftazidime/avibactam therapy was investigated and the underlying mechanisms elucidated. Two sequential isolates recovered before and after the ceftazidime/avibactam treatment were characterized by antimicrobial susceptibility testing, whole-genome sequencing, and functional and biochemical analyses. The initial isolate was susceptible to ceftazidime/avibactam, whereas the later isolate developed resistance (increase in MIC from 2 to 32 mg/L), accompanied by collateral carbapenem susceptibility. Both isolates co-produced a novel BEL variant (designated BEL-5) and an OXA-2 enzyme, encoded by adjacent genes within a class one integron embedded in a 31,623-bp IncP plasmid. The resistant isolate harbored a previously undescribed OXA-2 variant, designated OXA-1381, carrying a W157L substitution in the Ω-loop. Cloning experiments demonstrated that OXA-1381 is an extended-spectrum variant conferring increased resistance to ceftazidime/avibactam and ceftolozane/tazobactam but decreased resistance to carbapenems. Kinetic analyses revealed a marked increase in the affinity and catalytic efficiency of OXA-1381 against ceftazidime and ceftolozane, while showing reduced hydrolytic activity against meropenem, consistent with the observed phenotypic trade-off. Inhibition assays showed similar susceptibility to avibactam for both enzymes, confirming that resistance was driven by enhanced hydrolysis rather than by impaired inhibition. The findings document the in vivo evolution of ceftazidime/avibactam resistance in an ESBL-producing P. aeruginosa background, mediated by structural modification of a narrow-spectrum OXA-2 enzyme. In addition, they highlight the potential of integron-borne genes encoding “silent” β-lactamases to evolve under antibiotic pressure and compromise the activity of last-line agents.


  • Open Access

    FTIR typing of the emerging NDM-14-producing Klebsiella pneumoniae ST147 clone

    by Pablo Aja-Macaya, Lara Díaz Formoso, Tania Blanco-Martín, Lorena López-Cerero, Cristóbal del Rosario-Quintana, Diego García-Martínez de Artola, Germán Bou, Jorge Arca-Suárez, Marina Oviaño

    The emergence and rapid dissemination of NDM-14-producing Klebsiella pneumoniae ST147 represents a major challenge for infection control, requiring timely and reliable outbreak detection tools. In this study, we evaluated Fourier-transform infrared (FTIR) spectroscopy as a rapid typing method for outbreak investigation and compared its performance with whole-genome sequencing (WGS). A collection of 64 carbapenemase-producing K. pneumoniae isolates, including 30 NDM-14-producing ST147 isolates associated with a regional outbreak in the Canary Islands, was analyzed using FTIR spectroscopy and WGS. FTIR-based clustering was optimized using the polysaccharide spectral region and a customized distance cutoff. Genomic relatedness was assessed using multilocus sequence typing, core-genome single-nucleotide polymorphism (SNP) analysis at multiple thresholds, and clustering agreement indices. FTIR identified a dominant spectral cluster comprising 31 isolates, capturing all outbreak-related isolates with 100% sensitivity and 97% specificity. FTIR clustering showed concordance with genomic outbreak definitions at stringent SNP thresholds (10–18 SNPs), with accuracy exceeding 98%. Pairwise distance analysis revealed low FTIR dissimilarity among closely related isolates, whereas increased dispersion occurred at intermediate genomic distances (15–30 SNPs). Agreement indices showed improved concordance as genomic stringency increased, with the Modified Adjusted Rand Index values reaching 94.75 at the 10-SNP threshold. Importantly, FTIR identified an NDM-14-producing isolate from a distinct clonal background. Overall, FTIR spectroscopy provides a rapid and reliable first-line screening tool for identifying homogeneous outbreak clusters. However, due to lineage-dependent behavior and limited resolution at intermediate genomic distances, WGS remains essential for confirmatory analysis and precise delineation of transmission events. IMPORTANCE: The rapid spread of multidrug-resistant Klebsiella pneumoniae poses a major challenge for infection control, particularly during hospital outbreaks where timely identification of transmission is essential. In this study, we evaluate Fourier-transform infrared (FTIR) spectroscopy as a rapid typing approach and compare its performance with whole-genome sequencing in the context of an outbreak caused by NDM-14-producing K. pneumoniae ST147. Our results show that FTIR can reliably identify highly related isolates within a clonal outbreak, supporting early outbreak recognition. However, its performance is influenced by the underlying genomic structure of the population and may require dataset-specific optimization. These findings highlight the potential of FTIR as a first-line screening tool while emphasizing the need for cautious interpretation and integration with genomic methods for accurate outbreak delineation.

  • Open Access

    Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

    by Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Tania Blanco-Martín, Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto, Inmaculada López-Hernández, Belén Aracil García, Alejandro Beceiro, Germán Bou, et al.

    We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.


  • Open Access

    Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa

    by Lucía González-Pinto, Laura Monge-Olivares, Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía Sánchez-Peña, María Antonia Gomis-Font, Salud Rodríguez-Pallares, Tania Blanco-Martín, Lorena López-Cerero, Alejandro Beceiro, et al.

    We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The bla OXA-1054 gene was cloned in parallel with bla OXA-48 and bla OXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The bla OXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa , including carbapenems and β-lactam/β-lactamase inhibitor combinations.

  • Open Access

    Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam

    by Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto, Biel Taltavull, María Tarriño-León, María del Mar Gallardo-García, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Miriam Moscoso, et al.

    We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink. All isolates belonged to clone ST253 and exhibited difficult-to-treat resistance, including resistance to imipenem/relebactam and meropenem/vaborbactam. Genomic analysis confirmed a plasmid-encoded bla KPC-2 and OprD deficiency. Functional assays demonstrated synergy between KPC-2 production and porin loss on resistance to carbapenem/β-lactamase inhibitors. The findings highlight the clinical threat posed by KPC-producing P. aeruginosa .


  • Open Access

    Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

    by Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, Tania Blanco-Martín, Lucía González-Pinto, Gloria Pérez-Rodríguez, Christophe Le Terrier, Inés Portillo-Calderón, Esther Recacha, Cristina Riazzo, et al.

    Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.


  • Open Access

    Dispersal history of SARS-CoV-2 in Galicia, Spain

    by Pilar Gallego-García, Nuria Estévez-Gómez, Loretta De Chiara, Pilar Alvariño, Pedro M. Juiz-González, Isabel Torres-Beceiro, Margarita Poza, Juan A. Vallejo, Soraya Rumbo-Feal, Kelly Conde-Pérez, et al.

    The dynamics of SARS-CoV-2 transmission are influenced by a variety of factors, including social restrictions and the emergence of distinct variants. In this study, we delve into the origins and dissemination of the Alpha, Delta, and Omicron variants of concern in Galicia, northwest Spain. For this, we leveraged genomic data collected by the EPICOVIGAL Consortium and from the GISAID database, along with mobility information from other Spanish regions and foreign countries. Our analysis indicates that initial introductions during the Alpha phase were predominantly from other Spanish regions and France. However, as the pandemic progressed, introductions from Portugal and the USA became increasingly significant. Notably, Galicia's major coastal cities emerged as critical hubs for viral transmission, highlighting their role in sustaining and spreading the virus. This research emphasizes the critical role of regional connectivity in the spread of SARS-CoV-2 and offers essential insights for enhancing public health strategies and surveillance measures.

  • Open Access

    The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

    by Kelly Conde‐Pérez, Pablo Aja‐Macaya, Elena Buetas, Noelia Trigo‐Tasende, Mohammed Nasser‐Ali, Soraya Rumbo‐Feal, Paula Nión, Elsa Martín‐De Arribas, Lara S. Estévez, Begoña Otero‐Alén, et al.

    The incidence of colorectal cancer (CRC) has increased worldwide, and early diagnosis is crucial to reduce mortality rates. Therefore, new noninvasive biomarkers for CRC are required. Recent studies have revealed an imbalance in the oral and gut microbiomes of patients with CRC, as well as impaired gut vascular barrier function. In the present study, the microbiomes of saliva, crevicular fluid, feces, and non‐neoplastic and tumor intestinal tissue samples of 93 CRC patients and 30 healthy individuals without digestive disorders (non‐CRC) were analyzed by 16S rRNA metabarcoding procedures. The data revealed that Parvimonas, Fusobacterium, and Bacteroides fragilis were significantly over‐represented in stool samples of CRC patients, whereas Faecalibacterium and Blautia were significantly over‐abundant in the non‐CRC group. Moreover, the tumor samples were enriched in well‐known periodontal anaerobes, including Fusobacterium, Parvimonas, Peptostreptococcus, Porphyromonas, and Prevotella. Co‐occurrence patterns of these oral microorganisms were observed in the subgingival pocket and in the tumor tissues of CRC patients, where they also correlated with other gut microbes, such as Hungatella. This study provides new evidence that oral pathobionts, normally located in subgingival pockets, can migrate to the colon and probably aggregate with aerobic bacteria, forming synergistic consortia. Furthermore, we suggest that the group composed of Fusobacterium, Parvimonas, Bacteroides, and Faecalibacterium could be used to design an excellent noninvasive fecal test for the early diagnosis of CRC. The combination of these four genera would significantly improve the reliability of a discriminatory test with respect to others that use a single species as a unique CRC biomarker.